160,985 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the 3rd quarter, HoldingsChannel.com reports. The fund purchased 160,985 shares of the biotechnology company’s stock, valued at approximately $5,552,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of ARWR. Marshall Wace LLP raised its stake in Arrowhead Pharmaceuticals by 3,507.8% in the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after purchasing an additional 2,096,238 shares in the last quarter. Norges Bank bought a new stake in shares of Arrowhead Pharmaceuticals in the second quarter worth $30,414,000. Invesco Ltd. increased its stake in shares of Arrowhead Pharmaceuticals by 142.8% in the second quarter. Invesco Ltd. now owns 762,665 shares of the biotechnology company’s stock valued at $12,050,000 after buying an additional 448,585 shares during the period. Goldman Sachs Group Inc. increased its position in Arrowhead Pharmaceuticals by 34.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock valued at $22,189,000 after purchasing an additional 447,456 shares during the period. Finally, Assenagon Asset Management S.A. increased its position in shares of Arrowhead Pharmaceuticals by 1,388.6% during the third quarter. Assenagon Asset Management S.A. now owns 380,625 shares of the biotechnology company’s stock worth $13,128,000 after buying an additional 355,056 shares during the period. Institutional investors and hedge funds own 62.61% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ARWR. The Goldman Sachs Group lifted their price objective on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, January 7th. Chardan Capital upped their price objective on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. B. Riley raised their target price on Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Royal Bank Of Canada upped their price objective on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a report on Thursday, December 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $81.67.

Arrowhead Pharmaceuticals Stock Down 0.3%

Shares of NASDAQ ARWR opened at $66.82 on Tuesday. The stock has a market capitalization of $9.08 billion, a P/E ratio of -835.15 and a beta of 1.21. The firm’s 50 day simple moving average is $62.95 and its two-hundred day simple moving average is $40.59. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $76.76. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.86 and a quick ratio of 4.86.

Insiders Place Their Bets

In related news, insider James C. Hamilton sold 40,164 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $63.11, for a total value of $2,534,750.04. Following the completion of the transaction, the insider directly owned 171,958 shares in the company, valued at $10,852,269.38. This trade represents a 18.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Patrick O’brien sold 49,493 shares of Arrowhead Pharmaceuticals stock in a transaction on Monday, January 5th. The shares were sold at an average price of $63.11, for a total value of $3,123,503.23. Following the transaction, the chief operating officer owned 474,908 shares of the company’s stock, valued at $29,971,443.88. The trade was a 9.44% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 510,836 shares of company stock worth $33,603,060. Insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.